lisinopril / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 124 Diseases   24 Trials   24 Trials   2135 News 


«12...15161718192021222324252627»
  • ||||||||||  Telmitan (telmisartan) / Orient Europharma
    Journal:  IMPROVEMENT OF TREATMENT IN PERSONS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS. (Pubmed Central) -  May 2, 2019   
    In coexistent patients with greater than 10 pg/ml level of endothelin-1 and 80 mg/day dose of telmisartan, the level of albumin excretion rate was reduced by 4,9% (p=0,0435), and left ventricular mass index - by 3,1% (p<0,0001). If the level of this indicator is less than 10 pg/ml, the dose of telmisartan is 40 mg/day, if the level of endothelin-1 is more than 10 pg/ml, the dose of telmisartan is 80 mg/day.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial termination, Surgery:  OPTMIZE-OS: Risk Factor Control Before Orthopedic Surgery (clinicaltrials.gov) -  Apr 29, 2019   
    P4,  N=198, Terminated, 
    If the level of this indicator is less than 10 pg/ml, the dose of telmisartan is 40 mg/day, if the level of endothelin-1 is more than 10 pg/ml, the dose of telmisartan is 80 mg/day. Suspended --> Terminated; Low recruitment / DSMB approval to halt recruitment
  • ||||||||||  lisinopril / generics
    Clinical, Journal:  Unusual Case of a Massive Macroglossia Secondary to Myxedema: A Case Report and Literature Review. (Pubmed Central) -  Apr 26, 2019   
    ...Substantial enlargement of the tongue (16 cm long × 10 cm wide) was first attributed to angioedema, which was refractory to the discontinuation of lisinopril and a C1 esterase inhibitor...She recovered unremarkably, with excellent cosmesis and preservation of lingual and hypoglossal function. There are some case reports of massive macroglossia but none with myxedema as the primary etiology.
  • ||||||||||  Tamoxis (tamoxifen) / Bioprofarma, Tekturna (aliskiren) / PDL
    Journal:  Attenuation of Accelerated Renal Cystogenesis in Pkd1 Mice by Renin Angiotensin System Blockade. (Pubmed Central) -  Apr 26, 2019   
    There are some case reports of massive macroglossia but none with myxedema as the primary etiology. These results indicate that suppressing Agt using an ASO slowed the progression of accelerated cystic kidney disease induced by unilateral nephrectomy in Pkd1 mice by suppressing intrarenal RAS, mTOR pathway and cell proliferation.
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Trial completion, Adverse events:  Lisinopril or Coreg CR (clinicaltrials.gov) -  Apr 26, 2019   
    P2,  N=468, Completed, 
    These results indicate that suppressing Agt using an ASO slowed the progression of accelerated cystic kidney disease induced by unilateral nephrectomy in Pkd1 mice by suppressing intrarenal RAS, mTOR pathway and cell proliferation. Active, not recruiting --> Completed
  • ||||||||||  lisinopril / generics, spironolactone / generics
    Journal, Combination therapy:  Photocurable Bioinks for the 3D Pharming of Combination Therapies. (Pubmed Central) -  Apr 10, 2019   
    High-performance liquid chromatography (HPLC) analysis showed sustained release profiles for each of the loaded compounds. This study confirms the potential of material jetting in conjunction with binder jetting techniques (powder-bed 3D printing), for the production of combination therapy oral dosage forms involving both hydrophilic and hydrophobic drugs.
  • ||||||||||  Frumeron (indapamide) / Remedica
    Clinical, Journal:  'Temporary Plasticiser': A Novel Solution to Fabricate 3D Printed Patient-Centred Cardiovascular 'Polypill' Architectures. (Pubmed Central) -  Apr 7, 2019   
    In addition to the multilayer architecture offering a higher flexibility in dose titration and a more adaptive solution to meet the expectations of patient-centred therapy, we identify that it also allows orchestrating the release of drugs of different physicochemical characteristics. Adopting such an approach opens up a pathway towards low-cost multidrug delivery systems such as tablets, stents or implants for wider range of globally approved actives.
  • ||||||||||  enalapril / generics, lisinopril / generics, eplerenone / generics
    Retrospective data, Journal:  Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-Analysis. (Pubmed Central) -  Mar 23, 2019   
    According to the present analysis, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers could represent the best choice as antihypertensive treatment for pediatric hypertension. However, because of the paucity of available data for the other classes of antihypertensive drugs, definitive conclusions are not allowed and further randomized controlled trials are warranted.
  • ||||||||||  lisinopril / generics, fosinopril / generics
    Journal:  A method using angiotensin converting enzyme immobilized on magnetic beads for inhibitor screening. (Pubmed Central) -  Mar 21, 2019   
    As a result, epiberberine and fangchinoline with certain ACE inhibitory activities were screened out in the assay and validated. The results demonstrate the usefulness of this screening method using ACE immobilized on magnetic beads and the advantage of great efficiency with respect to both time and reagents for screening ACE inhibitors.
  • ||||||||||  lercanidipine / Generic mfg., furosemide / Generic mfg., lisinopril / Generic mfg.
    Trial completion date, Trial primary completion date:  Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01) (clinicaltrials.gov) -  Feb 22, 2019   
    P4,  N=106, Recruiting, 
    The results demonstrate the usefulness of this screening method using ACE immobilized on magnetic beads and the advantage of great efficiency with respect to both time and reagents for screening ACE inhibitors. Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2018 --> Dec 2019
  • ||||||||||  candesartan cilexetil / Generic mfg., lisinopril / Generic mfg.
    Trial completion:  CALIBREX: CAndesartan vs LIsinopril Effects on the BRain (clinicaltrials.gov) -  Jan 24, 2019   
    P3,  N=176, Completed, 
    Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2018 --> Dec 2019 Active, not recruiting --> Completed
  • ||||||||||  lisinopril / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Clinical Bioequivalence Study on Two Lisinopril Tablets 20mg Formulations (clinicaltrials.gov) -  Jan 16, 2019   
    P1,  N=30, Not yet recruiting, 
    Active, not recruiting --> Completed Trial completion date: Apr 2019 --> Apr 2020 | Initiation date: Oct 2018 --> Oct 2019 | Trial primary completion date: Mar 2019 --> Mar 2020
  • ||||||||||  lisinopril / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  A Pilot Study: Preventing Adverse Remodelling Following Pacemaker Implantation (clinicaltrials.gov) -  Nov 28, 2018   
    P2,  N=75, Not yet recruiting, 
    N=550 --> 4422 Trial completion date: Sep 2020 --> Sep 2021 | Initiation date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2020 --> Jul 2021
  • ||||||||||  lisinopril / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension (clinicaltrials.gov) -  Sep 20, 2018   
    P4,  N=13, Completed, 
    Trial completion date: Sep 2020 --> Sep 2021 | Initiation date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2020 --> Jul 2021 Recruiting --> Completed | N=33 --> 13 | Trial completion date: Jan 2016 --> Sep 2018 | Trial primary completion date: Sep 2015 --> May 2017
  • ||||||||||  lisinopril / Generic mfg.
    Enrollment open:  Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria (clinicaltrials.gov) -  Sep 19, 2018   
    P2,  N=280, Recruiting, 
    Recruiting --> Completed | N=33 --> 13 | Trial completion date: Jan 2016 --> Sep 2018 | Trial primary completion date: Sep 2015 --> May 2017 Not yet recruiting --> Recruiting
  • ||||||||||  Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date:  REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) -  Aug 20, 2018   
    P4,  N=6800, Recruiting, 
    Recruiting --> Completed | Trial completion date: Dec 2020 --> Jun 2018 | Trial primary completion date: Jun 2020 --> Jun 2018 N=4000 --> 6800 | Trial completion date: Feb 2019 --> Jun 2022 | Trial primary completion date: Feb 2019 --> Dec 2021 | Initiation date: Dec 2015 --> Apr 2016
  • ||||||||||  lisinopril / Generic mfg.
    Trial completion date, Trial primary completion date:  Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer (clinicaltrials.gov) -  Aug 14, 2018   
    P=N/A,  N=50, Active, not recruiting, 
    N=4000 --> 6800 | Trial completion date: Feb 2019 --> Jun 2022 | Trial primary completion date: Feb 2019 --> Dec 2021 | Initiation date: Dec 2015 --> Apr 2016 Trial completion date: Jul 2018 --> Nov 2018 | Trial primary completion date: Jul 2018 --> Nov 2018
  • ||||||||||  lisinopril / Generic mfg.
    Enrollment change, Trial primary completion date:  Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria (clinicaltrials.gov) -  Jul 31, 2018   
    P2,  N=280, Not yet recruiting, 
    Trial completion date: Jul 2018 --> Nov 2018 | Trial primary completion date: Jul 2018 --> Nov 2018 N=200 --> 280 | Trial primary completion date: Nov 2020 --> Feb 2022
  • ||||||||||  lisinopril / Generic mfg.
    Trial completion, Enrollment change:  Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies (clinicaltrials.gov) -  Jun 15, 2018   
    P2/3,  N=63, Completed, 
    Our RNA-Seq analysis suggests that ASI reduce the malignant potential of cancer cells and stimulate the immune microenvironment in primary PDAC. Enrolling by invitation --> Completed | N=120 --> 63
  • ||||||||||  Hygroton (chlortalidone) / Alliance, NN1213 / Novo Nordisk
    Phase classification:  Genetics of Hypertension Associated Treatments (GenHAT) (clinicaltrials.gov) -  Apr 6, 2018   
    P,  N=37939, Completed, 
    Enrolling by invitation --> Completed | N=120 --> 63 Phase classification: P=N/A --> P
  • ||||||||||  atorvastatin / Generic mfg., lisinopril / Generic mfg.
    Trial completion date, Trial suspension, Trial primary completion date, Surgery:  OPTMIZE-OS: Risk Factor Control Before Orthopedic Surgery (clinicaltrials.gov) -  Mar 14, 2018   
    P4,  N=198, Suspended, 
    Phase classification: P=N/A --> P Trial completion date: May 2017 --> Dec 2018 | Terminated --> Suspended | Trial primary completion date: May 2017 --> Dec 2018
  • ||||||||||  Bystolic (nebivolol) / Menarini, AbbVie
    Trial completion, Trial completion date:  FINE-PATH: Non-invasive Haemodynamic Assessment in Hypertension (clinicaltrials.gov) -  Mar 13, 2018   
    P=N/A,  N=144, Completed, 
    Trial completion date: May 2017 --> Dec 2018 | Terminated --> Suspended | Trial primary completion date: May 2017 --> Dec 2018 Recruiting --> Completed | Trial completion date: Dec 2015 --> Dec 2017
  • ||||||||||  lisinopril / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy. (clinicaltrials.gov) -  Mar 3, 2018   
    P4,  N=200, Not yet recruiting, 
    Phase classification: P=N/A --> P3 Trial completion date: Dec 2019 --> Mar 2020 | Initiation date: Jan 2018 --> Mar 2018 | Trial primary completion date: Jan 2019 --> Mar 2019
  • ||||||||||  Enrollment open, Trial initiation date:  WARRIOR: Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (clinicaltrials.gov) -  Feb 14, 2018   
    P4,  N=4422, Recruiting, 
    Trial completion date: Dec 2019 --> Mar 2020 | Initiation date: Jan 2018 --> Mar 2018 | Trial primary completion date: Jan 2019 --> Mar 2019 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Feb 2018
  • ||||||||||  lisinopril / Generic mfg.
    Trial initiation date:  Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria (clinicaltrials.gov) -  Dec 14, 2017   
    P2,  N=200, Not yet recruiting, 
    Compared with chlorthalidone, treatment with lisinopril is not associated with a meaningful reduction in incident AF or AFL among older adults with a history of hypertension. Initiation date: Nov 2017 --> Feb 2018
  • ||||||||||  atorvastatin / Generic mfg., lisinopril / Generic mfg.
    Trial primary completion date, Surgery:  OPTMIZE-OS: Risk Factor Control Before Orthopedic Surgery (clinicaltrials.gov) -  Dec 6, 2017   
    P4,  N=198, Terminated, 
    Initiation date: Nov 2017 --> Feb 2018 Trial primary completion date: Dec 2017 --> May 2017
  • ||||||||||  lisinopril / Generic mfg.
    Journal:  Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade. (Pubmed Central) -  Dec 3, 2017   
    Trial primary completion date: Dec 2017 --> Jul 2018 Dual renin-angiotensin system blockade was associated with an increased risk of AKI compared with monotherapy, but AKI in the setting of monotherapy was associated with lower rates of recovery of kidney function, higher mortality, and higher risk of progression of kidney disease.
  • ||||||||||  lisinopril / Generic mfg.
    Trial primary completion date:  Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis (clinicaltrials.gov) -  Oct 12, 2017   
    P2a,  N=20, Recruiting, 
    Dual renin-angiotensin system blockade was associated with an increased risk of AKI compared with monotherapy, but AKI in the setting of monotherapy was associated with lower rates of recovery of kidney function, higher mortality, and higher risk of progression of kidney disease. Trial primary completion date: Mar 2017 --> Jun 2018
  • ||||||||||  candesartan cilexetil / Generic mfg., lisinopril / Generic mfg.
    Enrollment closed, Enrollment change, Trial primary completion date:  CALIBREX: CAndesartan vs LIsinopril Effects on the BRain (clinicaltrials.gov) -  Oct 4, 2017   
    P3,  N=168, Active, not recruiting, 
    Trial primary completion date: Mar 2017 --> Jun 2018 Recruiting --> Active, not recruiting | N=140 --> 168 | Trial primary completion date: Dec 2017 --> Nov 2018
  • ||||||||||  Phase classification:  COACH: Reducing Total Cardiovascular Risk in an Urban Community (clinicaltrials.gov) -  Sep 15, 2017   
    P4,  N=525, Completed, 
    Recruiting --> Active, not recruiting | N=140 --> 168 | Trial primary completion date: Dec 2017 --> Nov 2018 Phase classification: P=N/A --> P4
  • ||||||||||  lisinopril / Generic mfg.
    Journal:  Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). (Pubmed Central) -  Aug 26, 2017   
    Compared with those randomized to chlorthalidone, participants randomized to amlodipine (odds ratio, 1.20; 95% confidence interval [CI], 1.10-1.31), lisinopril (odds ratio, 1.88; 95% CI, 1.73-2.03), and doxazosin (odds ratio, 1.65; 95% CI, 1.52-1.78) had higher adjusted odds ratios associated with being a nonimmediate responder (versus immediate responder)...The SBP response trajectories provided superior discrimination for predicting downstream adverse cardiovascular events than classification based on difference in SBP between the first 2 measurements, SBP at 6 months, and average SBP during the first 6 months. Our findings demonstrate heterogeneity in response to antihypertensive therapies and show that chlorthalidone is associated with more favorable initial response than the other medications.
  • ||||||||||  lisinopril / Generic mfg., carvedilol controlled-release / Generic mfg.
    Enrollment change:  Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives (clinicaltrials.gov) -  Aug 9, 2017   
    P1,  N=62, Completed, 
    Our findings demonstrate heterogeneity in response to antihypertensive therapies and show that chlorthalidone is associated with more favorable initial response than the other medications. N=40 --> 62